Optimal Integration of Machine Learning for Distinct Classification and Activity State Determination in Multiple Sclerosis and Neuromyelitis Optica
Maha GharaibehWlla AbedalazizNoor Aldeen AlawadHasan GharaibehAhmad NasayrehMwaffaq El-HeisMaryam AltalhiAgostino ForestieroLaith Abualigah
7
Citation
48
Reference
10
Related Paper
Citation Trend
Abstract:
The intricate neuroinflammatory diseases multiple sclerosis (MS) and neuromyelitis optica (NMO) often present similar clinical symptoms, creating challenges in their precise detection via magnetic resonance imaging (MRI). This challenge is further compounded when detecting the active and inactive states of MS. To address this diagnostic problem, we introduce an innovative framework that incorporates state-of-the-art machine learning algorithms applied to features culled from MRI scans by pre-trained deep learning models, VGG-NET and InceptionV3. To develop and test this methodology, we utilized a robust dataset obtained from the King Abdullah University Hospital in Jordan, encompassing cases diagnosed with both MS and NMO. We benchmarked thirteen distinct machine learning algorithms and discovered that support vector machine (SVM) and K-nearest neighbor (KNN) algorithms performed superiorly in our context. Our results demonstrated KNN’s exceptional performance in differentiating between MS and NMO, with precision, recall, F1-score, and accuracy values of 0.98, 0.99, 0.99, and 0.99, respectively, using leveraging features extracted from VGG16. In contrast, SVM excelled in classifying active versus inactive states of MS, achieving precision, recall, F1-score, and accuracy values of 0.99, 0.97, 0.98, and 0.98, respectively, using leveraging features extracted from VGG16 and VGG19. Our advanced methodology outshines previous studies, providing clinicians with a highly accurate, efficient tool for diagnosing these diseases. The immediate implication of our research is the potential to streamline treatment processes, thereby delivering timely, appropriate care to patients suffering from these complex diseases.Keywords:
Neuromyelitis Optica
Neuromyelitis Optica
Aquaporin 4
Optic neuritis
Demyelinating disease
Spectrum disorder
Cite
Citations (2,097)
Abstract For a long time, the most important inflammatory demyelinating diseases of the central nervous system ( CNS ), for example, multiple sclerosis ( MS ) and neuromyelitis optica ( NMO ), were extremely hard to differentiate, often with severe consequences for affected patients. This changed with the discovery of NMO ‐immunoglobulin G ( IgG ), a specific autoantibody which was detected in the vast majority of NMO patients, and with the demonstration that this autoantibody targets aquaporin 4 ( AQP 4), a water channel found on astrocytes in the CNS . These findings paved the way for the generation of experimental models of NMO . This chapter will discuss the contribution of experimental models to NMO research and what key questions remain to be addressed.
Neuromyelitis Optica
Aquaporin 4
Demyelinating Disorder
Cite
Citations (50)
The specificity of the aquaporin-4 antibody to predict recurrent inflammatory central nervous system disease has led to the design of the 2015 neuromyelitis optica spectrum disorder criteria which capture all aquaporin-4 antibody seropositive patients.The purpose of this study was to compare treatment outcomes in aquaporin-4 antibody seropositive patients who met the previous 2006 clinical criteria for neuromyelitis optica with patients who meet the 2015 neuromyelitis optica spectrum disorder criteria.The study involved a three-center retrospective chart review of clinical outcomes among aquaporin-4 patients diagnosed with neuromyelitis optica and neuromyelitis optica spectrum disorder.Hazard ratios of relapse during immunosuppressive therapy, relative to pre-therapy, were not significantly different for patients who met the 2006 criteria of neuromyelitis optica versus the 2015 neuromyelitis optica spectrum disorder criteria among those treated with azathioprine ( p = 0.24), mycophenolate mofetil ( p = 0.63), or rituximab ( p = 0.97).Reductions in the hazard of relapse during treatment with immunosuppressive therapies, relative to average pre-treatment, were not different for aquaporin-4 antibody seropositive patients categorized using the 2006 criteria of neuromyelitis optica and the 2015 neuromyelitis optica spectrum disorder criteria. These therapeutic findings support the design of the 2015 neuromyelitis optica spectrum disorder criteria which capture all aquaporin-4 antibody seropositive patients.
Neuromyelitis Optica
Spectrum disorder
Aquaporin 4
Cite
Citations (16)
Neuromyelitis optica, also known as Devic disease, was identified in the 19th century, is one of the inflammatory idiopathic demyelinating diseases of the central nervous system, often mistaken for severe multiple sclerosis. In 1999 it had been proposed diagnostic criteria for neuromyelitis optica, but in 2006 these criteria were revised by Dean Wingerchuck. These criteria are 99% sensitive and 90% specific for differentiating neuromyelitis optica from multiple sclerosis that present with optic neuritis or a myelitis syndrome. In the following article we present clinical, spinal and cerebral MR imaging, serological and aspects of cerebrospinal fluid examination features of neuromyelitis optica and the revised criteria of neuromyelitis optica established in 2006. The recently identified serum antibody biomarker: neuromyelitis optica immunoglobulin G (NMO Ig G), which target aquaporin 4 water channel, distinguish neuromyelitis optica from multiple sclerosis, is one of the revised criteria of neuromyelitis optica.
Neuromyelitis Optica
Optic neuritis
Aquaporin 4
Demyelinating disease
Cite
Citations (1)
We review recent advances in neuromyelitis optica, an idiopathic inflammatory demyelinating disease of the central nervous system predominantly affecting optic nerves and spinal cord. We concentrate on a recently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis.NMO-IgG is detected by indirect immunofluorescence. Its presence and specificity for neuromyelitis optica was confirmed in diverse populations. Seropositivity is now incorporated into new diagnostic criteria for neuromyelitis optica. Testing for this biomarker has suggested that the neuromyelitis optica spectrum is broader than previously recognized. Recently, the molecular target of NMO-IgG was identified as aquaporin-4. Immunopathologic studies suggest that loss of aquaporin-4 immunostaining is detectable in early lesions of neuromyelitis optica. A B-cell-specific monoclonal antibody, rituximab, may be an effective treatment even in patients not responding to other treatments.Clinical, radiologic, and immunologic features distinguish neuromyelitis optica from other severe cases of multiple sclerosis. NMO-IgG is the first specific marker for a central nervous system demyelinating disease. The discovery of aquaporin-4 as the putative target of NMO-IgG, and recent data suggesting that aquaporin-4-specific antibodies are pathogenic may enhance our understanding of idiopathic inflammatory demyelinating diseases and their treatment.
Neuromyelitis Optica
Aquaporin 4
Optic neuritis
Demyelinating disease
Cite
Citations (83)
Neuromyelitis optica (Devic's disease) is an idiopathic inflammatory demyelinating disease of central nervous system that preferentially affects the optic nerve and spinal cord. Although neuromyelitis optica had long been thought of as a variant of multiple sclerosis, it was understood as a different entity. A 28 year old woman presented with urinary and fecal incontinence and numbness on her arms and legs. Neuromyelitis optica was diagnosed according to her clinic and laboratory findings. It is important to distinguish between multiple sclerosis and neuromyelitis optica because they have different management.
Neuromyelitis Optica
Demyelinating disease
Cite
Citations (2)
Neuromyelitis optica(NMO)is an inflammatory demyelinating disorder of the central nervous system(CNS)that predominantly affects the optic nerve and spinal cord. It has long been controversial about the concept whether NMO is an independent disease, or a subtype of multiple sclerosis(MS). In 2004, anti-AQP4 antibody was found in the sera of NMO patients, which gradually indicates that NMO is an independent disease different from MS. The discovery of anti-AQP4 antibody will not only contribute to the clinical diagnosis, early treatment and prognosis of NMO, but also make us do further research on NMO. We mainly reviewed the role of anti-AQP4 antibody in pathogenesis of NMO, detection methods and clinical significance of NMO.
Key words:
Neuromyelitis optica; Anti-aquaporin-4 antibody; Demyelinating disease
Neuromyelitis Optica
Demyelinating disease
Aquaporin 4
Spectrum disorder
Demyelinating Disorder
Pathogenesis
Optic neuritis
Cite
Citations (0)
Neuromyelitis Optica
Aquaporin 4
Eculizumab
Demyelinating disease
Cite
Citations (541)
Neuromyelitis Optica
Spectrum disorder
Presentation (obstetrics)
Cite
Citations (5)
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by relapses of optic neuritis and acute myelitis. The disease was referred to as the optic-spinal form of multiple sclerosis (OSMS) in Japan for a long period. A specific auto-antibody, NMO-IgG, was detected in the serum of NMO patients, and aquaporin-4 water channel protein was detected as its target antigen; aquaporin-4 water channel protein is localized at the end-feet of astrocytes. Because of the presence of this specific serum auto-antibody, most OSMS patients in Japan were found to exhibit a disease that was identical to NMO that affects individuals of the Western countries. Since the discovery of NMO-IgG, various clinical and histopathological features of this condition have been recognized; in addition the concept of NMO has been established in Japan as well as in many other countries.
Neuromyelitis Optica
Optic neuritis
Aquaporin 4
Demyelinating disease
Cite
Citations (2)